ISO 10993 Updates 2026: How Medical Device Manufacturers Can Prepare

## ISO 10993 Updates: A Guide to Selecting a Future-Ready Biocompatibility Lab With significant updates to the ISO 10993 series of standards anticipated around 2026, medical device manufacturers must evolve their approach to biological safety evaluation. The forthcoming changes are expected to further emphasize a comprehensive, risk-based methodology, moving away from a simple checklist of standard tests. This shift requires sponsors to partner with biocompatibility testing laboratories and contract research organizations (CROs) that possess deep toxicological expertise and a forward-looking perspective, not just the ability to execute standard protocols. Selecting the right partner is critical. A lab that understands the evolving landscape can help develop a lean, scientifically sound testing strategy that withstands regulatory scrutiny from the FDA and other global bodies. Conversely, a lab that is unprepared for these changes can lead to unnecessary testing, regulatory delays, and significant additional costs. The key is to look beyond basic accreditations and assess a lab's ability to integrate chemical, toxicological, and biological data into a cohesive safety argument that aligns with future expectations. ### Key Points * **Beyond Accreditation:** While ISO/IEC 17025 accreditation and Good Laboratory Practice (GLP) compliance are essential, they are only the starting point. True readiness lies in a lab's scientific depth and strategic foresight. * **Emphasis on Risk Assessment:** The updates to ISO 10993 will likely intensify the focus on a risk-based approach, as outlined in ISO 10993-1. This means the rationale for *not* performing a test is as important as the test data itself. * **Integrated Testing is Critical:** A future-ready lab must demonstrate expertise in integrating chemical characterization (ISO 10993-18) with toxicological risk assessment (ISO 10993-17) to inform and potentially reduce the need for traditional biological endpoint testing. * **Expertise Matters:** The qualifications of the lab's toxicologists and study directors are paramount. They should have demonstrable experience creating comprehensive Biological Evaluation Plans (BEPs) and defending testing strategies to regulatory authorities. * **Proactive Engagement:** Sponsors should begin vetting potential lab partners well in advance of needing to initiate testing, asking specific questions about how they are preparing for the upcoming ISO 10993 revisions and other regulatory trends. ## Understanding the Shift: From Checklist to Integrated Risk Management The evaluation of biocompatibility is moving away from a "checklist" mentality where a device is subjected to a pre-defined battery of tests based solely on its categorization. Instead, regulatory bodies like the FDA, in alignment with modern standards like ISO 10993-1, expect a holistic biological risk assessment. This process begins with a deep understanding of the device, including: * All materials of construction. * Manufacturing processes (e.g., sterilization, machining, cleaning). * The nature and duration of patient contact. * The intended clinical use and patient population. This information is used to develop a Biological Evaluation Plan (BEP), a foundational document that outlines the potential biological risks and proposes a strategy to address them. A well-constructed BEP often leverages chemical characterization and toxicological risk assessment to justify the testing plan, which may lead to a reduction in animal testing. This integrated approach is the cornerstone of modern biocompatibility evaluation and the focus of the anticipated 2026 updates. ## A Framework for Vetting Future-Ready Biocompatibility Labs To ensure a potential laboratory partner is prepared for this evolving landscape, sponsors should evaluate them across four key domains: Foundational Qualifications, Scientific and Regulatory Foresight, Integrated Risk-Based Approach, and Operational Excellence. ### 1. Foundational Qualifications (The Table Stakes) These are the non-negotiable requirements. Any lab under consideration must meet these baseline criteria. * **Accreditation and Compliance:** * **Question:** Can you provide your current ISO/IEC 17025 certificate of accreditation? Is it for the specific tests we require? * **What to look for:** The scope of accreditation should explicitly cover the relevant ISO 10993 parts. * **Good Laboratory Practice (GLP):** * **Question:** Do you conduct studies in compliance with FDA 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies)? * **What to look for:** Confirmation of GLP compliance is essential for data intended for submission to the FDA. * **Regulatory History:** * **Question:** Can you provide information on your history with regulatory agency inspections (e.g., FDA)? * **What to look for:** A clean inspection history indicates a culture of quality and compliance. ### 2. Scientific and Regulatory Foresight (Future-Proofing) This domain assesses a lab’s proactive engagement with the evolving regulatory and scientific landscape. * **Staying Current on Standards:** * **Question:** How does your team stay informed about draft international standards and upcoming changes to the ISO 10993 series? Are any of your staff members on standards committees? * **What to look for:** Proactive labs will have internal processes for monitoring standards development. Staff participation in committees (e.g., ISO, AAMI) is a strong indicator of leadership and deep expertise. * **Toxicology Team Expertise:** * **Question:** Can we review the credentials of your toxicologists? What is their experience in writing BEPs and Toxicological Risk Assessments (TRAs) for devices similar to ours? * **What to look for:** Look for board-certified toxicologists (e.g., DABT - Diplomate of the American Board of Toxicology) with specific experience in medical devices, not just pharmaceuticals or environmental toxicology. * **Adapting Test Protocols:** * **Question:** How do you adapt your test methods, such as cytotoxicity (ISO 10993-5) or sensitization (ISO 10993-10), to reflect new scientific principles or regulatory expectations (e.g., the move towards in vitro methods)? * **What to look for:** A forward-looking lab will be investing in and validating new alternative methods (NAMs) to reduce reliance on animal testing, a key goal of many regulatory bodies. ### 3. Integrated Risk-Based Approach (The Modern Strategy) This is the most critical domain for assessing readiness for the future of biocompatibility. It evaluates the lab's ability to connect different data streams into a single, cohesive argument. * **BEP Development Philosophy:** * **Question:** What is your process for developing a Biological Evaluation Plan? How do you use risk assessment to justify the proposed testing strategy? * **What to look for:** The lab should describe a collaborative process that starts with the device's materials and manufacturing, not a generic template. Their goal should be to build a scientific rationale to justify the testing plan. * **Integration of Chemistry and Toxicology:** * **Question:** How do your chemistry (ISO 10993-18) and toxicology (ISO 10993-17) teams work together? Can you provide an example of how chemical characterization data was used to create a toxicological risk assessment that reduced the need for long-term implantation studies? * **What to look for:** The best labs have tightly integrated teams. The analytical chemists should understand the toxicological endpoints, and the toxicologists must be able to interpret complex chemical data to assess patient risk. This synergy is essential. * **Data Interpretation and Reporting:** * **Question:** How are the final reports structured to present a complete biological safety narrative for a regulatory submission? * **What to look for:** The final documentation should not be a series of disconnected test reports. It should be a comprehensive biological evaluation report (BER) that synthesizes all the data—material information, chemistry, toxicology, and biological testing—into a persuasive safety argument. ### 4. Operational Excellence and Communication This domain covers the practical aspects of working with the lab. * **Capacity and Turnaround Time:** * **Question:** What is your current capacity for the tests we need? What are your typical turnaround times, and how do you communicate potential delays? * **What to look for:** Transparency is key. A good partner will provide realistic timelines and have a clear process for communicating updates. * **Sample Requirements and Handling:** * **Question:** What are your requirements for test articles, including quantity, preparation, and sterilization? * **What to look for:** Clear, detailed instructions that prevent delays caused by improper sample submission. * **Project Management and Support:** * **Question:** Who will be our primary point of contact? How often can we expect updates? Are your experts available to help answer regulatory questions about the data? * **What to look for:** A dedicated project manager and access to scientific experts for consultation are hallmarks of a customer-focused, partnership-oriented lab. ## Strategic Considerations and the Role of Q-Submission When a device presents a novel biocompatibility challenge—such as new materials, unique manufacturing processes, or a borderline intended use—early engagement with the FDA is highly recommended. A well-prepared Q-Submission can be used to gain feedback on the proposed Biological Evaluation Plan *before* testing begins. This is another area where a strategic lab partner adds immense value. An experienced lab can help a sponsor prepare the biocompatibility portion of the Q-Submission package, ensuring the testing rationale is clearly articulated and scientifically sound. Gaining FDA alignment on the testing strategy early in the process can significantly de-risk a project and prevent costly delays during the final marketing submission review. Sponsors should discuss a potential lab's experience with supporting Q-Submissions as part of the vetting process. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right CRO is a critical decision that impacts project timelines, budget, and regulatory success. A systematic approach to finding and comparing providers ensures that the selected partner has the technical capabilities, strategic foresight, and operational capacity to meet the project's needs. The process should involve creating a detailed Request for Proposal (RFP) that includes device information, patient contact details, and specific questions based on the vetting framework described above. When evaluating proposals, look beyond the price. Assess the depth of the proposed strategy, the experience of the assigned team, and the lab's commitment to a risk-based approach. A slightly more expensive proposal that includes a robust toxicological risk assessment upfront may ultimately be more cost-effective by reducing the need for extensive, long-term animal studies. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA References When preparing a biocompatibility strategy for an FDA submission, sponsors and their partners should refer to the latest regulatory documents. While specific guidances may apply depending on the device type, some foundational references include: * FDA's Guidance: **Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"**. This is the primary guidance document outlining FDA's thinking on the topic. * **21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies)**: The regulations governing the conduct of lab studies submitted to FDA. * **FDA's Q-Submission Program Guidance**: Provides instructions on how to formally engage with the FDA to get feedback on testing plans before submission. Sponsors should always consult the FDA website for the most current versions of these and other relevant documents. --- This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*